Guideline updated for initial management of advanced prostate cancer

For patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen deprivation therapy (ADT), and doublet therapy is inferior to triplet therapy, according to a guideline update published online April 3 in the Journal of Clinical Oncology.

This article was originally published on

You may also be interested in:

Read More:

Lawyers Lookup